Publications by authors named "Richard A Kay"

Claim this Profile
D
DP antagonism reduces airway smooth muscle mass in asthma by decreasing eosinophilia and myofibroblast recruitment.
Ruth Saunders, Himanshu Kaul, Rachid Berair, Sherif Gonem, Amisha Singapuri, Richard A Kay

Sci Transl Med· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fevipiprant, an oral prostaglandin DP receptor (CRTh2) antagonist, in allergic asthma uncontrolled on low-dose inhaled corticosteroids.
Eric D Bateman, Alfredo G Guerreros, Florian Brockhaus, Björn Holzhauer, Abhijit Pethe, Richard A Kay

Eur Respir J· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial.
Sherif Gonem, Rachid Berair, Amisha Singapuri, Ruth Hartley, Marie F M Laurencin, Richard A Kay

Lancet Respir Med· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The expression of migration stimulating factor, a potent oncofetal cytokine, is uniquely controlled by 3'-untranslated region-dependent nuclear sequestration of its precursor messenger RNA.
Richard A Kay, Ian R Ellis, Sarah J Jones, Stéphane Perrier, Margaret M Florence

Cancer Res· December 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Migration-stimulating factor: a genetically truncated onco-fetal fibronectin isoform expressed by carcinoma and tumor-associated stromal cells.
Seth L Schor, Ian R Ellis, Sarah J Jones, Robin Baillie, Kanjula Seneviratne, Richard A Kay

Cancer Res· December 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis